Background: In the United States, the routine age for human papillomavirus (HPV)
vaccination is 11 to 12 years, with catch-up vaccination through age 26 years for women and …

Background: Women older than 30 years are the main beneficiaries of improved cervical
cancer screening with human papillomavirus (HPV) DNA testing. The role of vaccination …

Background A nonavalent human papillomavirus (HPV) vaccine has been licensed for use
in women and men up to age 45 years in the United States. The cost-effectiveness of HPV …

Background The cost-effectiveness of prophylactic vaccination against human
papillomavirus types 16 (HPV-16) and 18 (HPV-18) is an important consideration for …

ContextRecently published results suggest that effective vaccines against cervical cancer—
associated human papillomavirus (HPV) may become available within the next decade …

Background: Human papillomavirus (HPV) vaccination was introduced in 2006 for females
and in 2011 for males. Objective: To estimate vaccine impact and effectiveness against …

The Advisory Committee on Immunization Practices presents the Adult Immunization
Schedule for 2010. It includes recommendations for bivalent human papillomavirus vaccine …

Background: Human papillomavirus (HPV) vaccine may be commercially available in a few
years. We explored the clinical benefits and cost-effectiveness of introducing an HPV16/18 …

INTRODUCTION: The objective of this study was to estimate the cost-effectiveness of adding
human papillomavirus (HPV) vaccination of 12-year-old males to a female-only vaccination …

Summary of the Clinical Problem Human papillomavirus is a highly prevalent sexually
transmitted infection. Prior to vaccination programs, 1 large study of US female individuals …